Hematologic Malignancy
Acute Lymphoblastic Leukemia
CI-CAN-00000400ALLExplore in graph →
Hematologic546 active trials12 approved drugs43 evidence items
- NCIt
- C3167
- DOID
- 9952
- MeSH
- D054198
- Other
- 3 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000400ALLExplore in graph →
Clinical trials
2,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (268)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00602134 | Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions | completed | N/A | 54 | Roxane LaboratoriesINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01491958 | Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation | completed | Phase 2 | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2018 |
| NCT02294552 | Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | completed | Phase 2 | 200 | Ivan S MoiseevOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT02924753 | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT01312818 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 2 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT03372642 | Effectiveness of Subtalar Arthroereisis With Endorthesis for Pediatric Flexible Flat Foot | completed | — | 60 | I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioOTHER | 0 | Dec 15, 2017 | clinicaltrials |
| NCT00098839 | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 134 | Children's Oncology GroupNETWORK | 4 | Dec 12, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00686556 | Total Marrow Irradiation for Refractory Acute Leukemia | completed | Phase 1 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01207076 | AHN-12 Biodistribution in Advanced Leukemia | terminated | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT02765997 | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01677949 | Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01110473 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | completed | Phase 1 | 52 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00701844 | Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | completed | N/A | 315 | University of North Carolina, Chapel HillOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00466895 | Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. | completed | Phase 1 | 37 | Leslie AndritsosOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03263208 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 / Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01786135 | A Safety Study of SGN-CD19A for B-Cell Lymphoma | completed | Phase 1 | 64 | Seagen Inc.INDUSTRY | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01457040 | Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00659425 | CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | completed | Phase 1 | 57 | MedImmune LLCINDUSTRY | 2 | Oct 2, 2017 | clinicaltrials |
| NCT03298828 | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | unknown | Phase 1 | 30 | Third Military Medical UniversityOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT02544438 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia(BSTPHASE1-01) | completed | Phase 1 / Phase 2 | 20 | BioSight Ltd.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT03281551 | Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma | unknown | Phase 1 | 50 | Pinze Lifetechnology Co. Ltd.INDUSTRY | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01116193 | Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia(RV-405 LAL) | completed | Phase 2 | 10 | Institut de Cancérologie de la LoireOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT03278145 | Dependence Receptors and Leukemia | unknown | — | 30 | Hospices Civils de LyonOTHER | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02345915 | Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia(LEA-JA) | unknown | N/A | 90 | Institut Paoli-CalmettesOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00988715 | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 | 17 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT03249636 | New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia | unknown | — | 50 | Assiut UniversityOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01169012 | PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias | completed | Phase 1 | 13 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT00929695 | Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease | completed | Phase 3 | 164 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01466179 | Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 225 | Amgen Research (Munich) GmbHINDUSTRY | 6 | Aug 18, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01383447 | Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2017 | clinicaltrials |
| NCT01324180 | Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 7, 2017 | clinicaltrials |
| NCT00186875 | Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 47 | St. Jude Children's Research HospitalOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT03141398 | Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group(CGMs) | withdrawn | — | 0 | Hamad Medical CorporationINDUSTRY | 0 | Jul 26, 2017 | clinicaltrials |
| NCT00437060 | Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia | completed | — | 233 | Children's Oncology GroupNETWORK | 4 | Jul 21, 2017 | clinicaltrials |
| NCT00462605 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2017 | clinicaltrials |
| NCT01643668 | Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT03118128 | Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia | completed | N/A | 102 | Hospital General de MexicoOTHER_GOV | 0 | Jul 6, 2017 | clinicaltrials |
| NCT01786096 | A Safety Study of SGN-CD19A for Leukemia and Lymphoma | completed | Phase 1 | 92 | Seagen Inc.INDUSTRY | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | N/A | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT03191773 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | unknown | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT03192683 | Modified "Providence" Pedi Cast-Sling vs.Cast and Sling | completed | N/A | 71 | LifespanOTHER | 0 | Jun 20, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2018source: clinicaltrials